Literature DB >> 6726822

An inhibitory effect of verapamil and diltiazem on the release of noradrenaline from ischaemic and reperfused hearts.

W G Nayler, W J Sturrock.   

Abstract

We have investigated whether Ca2+ antagonists reduce the amount of noradrenaline lost from the myocardium during periods of ischaemia and reperfusion. Hearts obtained from adult, male normotensive Sprague Dawley, Wistar Kyoto and spontaneously hypertensive rats were perfused in the Langendorff mode at 37 degrees C before being made globally ischaemic for either 15, 30 or 60 min. Some of the hearts were reperfused, and in some ECG records were made. 90-min normothermic aerobic perfusion failed to cause a significant change in left ventricular noradrenaline content. In Sprague Dawley and spontaneously hypertensive, but not Wistar Kyoto rats, 15 min ischaemia followed by 1 min reperfusion caused a significant (P less than 0.05) loss of noradrenaline. Extending the ischemic episode to 60 min resulted in a further loss of noradrenaline (P less than 0.005) in the Sprague Dawley, Wistar Kyoto and spontaneously hypertensive hearts and this loss was exacerbated upon reperfusion. Neither dl verapamil (2.5 X 10(-8) to 1.2 X 10(-6) mol/l) nor diltiazem (0.25 to 1.25 X 10(-6) mol/l) caused any change in the noradrenaline content of the aerobically perfused hearts. (1.25 X 10(-1) to 1.2 X 10(-1) mol/l) verapamil abolished the release of noradrenaline caused by 15 min ischaemia and reduced the release caused by 60 min ischaemia and 15 min reperfusion. The dose-response curve for verapamil was bell-shaped and the activity resided in the l form. Diltiazem (1.25 X 10(-6) mol/l but not 2.5 X 10(-1) mol/l) also abolished the loss of noradrenaline caused by short periods of ischaemia and reperfusion.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6726822     DOI: 10.1016/s0022-2828(84)80604-5

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  8 in total

1.  Effects of the calcium antagonist gallopamil on the increase of myocardial extracellular potassium activity during LAD occlusion in dogs.

Authors:  M Budden; M Kirchengast; K M Zhang; W Meesmann
Journal:  Basic Res Cardiol       Date:  1987 May-Jun       Impact factor: 17.165

Review 2.  Calcium channel antagonists, Part I: Fundamental properties: mechanisms, classification, sites of action.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

3.  Digitalis cardiotoxicity: cellular calcium overload a possible mechanism.

Authors:  J C Khatter; M Agbanyo; S Navaratnam; B Nero; R J Hoeschen
Journal:  Basic Res Cardiol       Date:  1989 Nov-Dec       Impact factor: 17.165

4.  Moderation of myocardial ischemia reperfusion injury by calcium channel and calmodulin receptor inhibition.

Authors:  Y Kimura; R M Engelman; J Rousou; J Flack; J Iyengar; D K Das
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

5.  Early intraneuronal mobilization and deamination of noradrenaline during global ischemia in the isolated perfused rat heart.

Authors:  L Carlsson; K H Graefe; U Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

6.  In vivo effects of the Ca2+-antagonist nimodipine on dopamine metabolism in mouse brain.

Authors:  E Pileblad; A Carlsson
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

7.  Depressed gut absorptive capacity early after trauma-hemorrhagic shock. Restoration with diltiazem treatment.

Authors:  G Singh; K I Chaudry; L C Chudler; I H Chaudry
Journal:  Ann Surg       Date:  1991-12       Impact factor: 12.969

8.  Anti-Inflammatory and Anti-Angiogenesis Effects of Verapamil on Rat Air Pouch Inflammation Model.

Authors:  Tahereh Eteraf-Oskouei; Sevda Mikaily Mirak; Moslem Najafi
Journal:  Adv Pharm Bull       Date:  2017-12-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.